Health Catalyst Inc

HCAT is in a Stage 2 advance with clear higher highs and higher lows and rising short-term EMAs, but price is extended above EMAs and overbought in the short term. Medium-term bias remains bullish after the recent breakout, yet execution should wait for a pullback into the rising 9/20 EMA zone or the lower portion of the breakout range before participation.

• ↑Q2 revenue $70.5M topped guidance; adjusted gross margin rose to 51% YoY
• ↑VitalWare divestiture cut $160M debt and $19M in annual interest expense
• ↓Consensus FY26 EPS cut to –$2.41 and revenue down to $247.4M from $268.2M